Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Randomized, Double-blind, Parallel Group, Multicenter Study to Evaluate Further Therapeutic Strategies With Guselkumab in Patients With Moderate-to-Severe Plaque-Type Psoriasis

NCT03818035 is registered in ClinicalTrials.gov with Janssen-Cilag International NV as lead sponsor.

NCT NCT03818035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03818035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Randomized, Double-blind, Parallel Group, Multicenter Study to Evaluate Further Therapeutic Strategies With Guselkumab in Patients With Moderate-to-Severe Plaque-Type Psoriasis
Lead sponsor
Janssen-Cilag International NV
Phase
Phase 3
Overall status
Completed
Start date
February 8, 2019
Completion date
January 7, 2025
Enrollment
880 (actual)
Sites
90

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis